Analyst Price Target is $21.67
▲ +164.23% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Myomo in the last 3 months. The average price target is $21.67, with a high forecast of $34.00 and a low forecast of $14.00. The average price target represents a 164.23% upside from the last price of $8.20.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Myomo. This Buy consensus rating has held steady for over two years.
Myomo, Inc. is a medical robotics company, which offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. It offers MyoPro, which is a myoelectric elbow, wrist, and hand orthosis that supports an impaired hand and arm while also enabling it to move again. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.